Related Experiment Video

Updated: Jul 22, 2026

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Using cancer genetics to guide the selection of anticancer drug targets

Archana Reddy1, William G Kaelin

  • 1Howard Hughes Medical Institute, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

Current Opinion in Pharmacology
|July 20, 2002
PubMed

Insights

Identifying cancer-driving genetic alterations reveals critical proteins for malignancy. Future cancer therapies will target proteins essential for cancer cell survival, building on current treatments that inhibit oncogenic mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Genetic alterations are increasingly understood as drivers of cancer development.
  • Mutated genes in human cancers indicate critical proteins and molecular pathways essential for malignancy.
  • Current targeted cancer therapies, like imatinib mesylate, inhibit oncogenic gain-of-function mutations.

Purpose of the Study:

  • To highlight the role of genetic alterations in identifying cancer targets.
  • To discuss the development of a second generation of anticancer agents.
  • To explore targeting proteins essential for cancer cell survival, regardless of mutation type.

Main Methods:

  • Analysis of recurrent gene mutations in human cancers.
  • Understanding oncogenic gain-of-function mutations.
  • Leveraging advances in somatic cell genetics and chemical biology.

Main Results:

  • Recurrently mutated genes identify key proteins and pathways in cancer evolution.
  • First-generation targeted agents inhibit biochemical activities from gain-of-function mutations.
  • Second-generation agents are being developed to target proteins essential for cancer survival.

Conclusions:

  • Targeting cancer-specific genetic alterations is a promising therapeutic strategy.
  • Future anticancer agents will focus on inhibiting proteins critical for cancer cell survival.
  • Advances in genetics and chemical biology will drive the development of novel cancer therapies.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...